A Safety Study Of Pregabalin In Fibromy… | Clinical Trial

Key information

Conditions

Fibromyalgia Muscular Diseases Musculoskeletal Diseases Nervous System Diseases Neuromuscular Diseases Rheumatic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Pfizer Investigational Site, Little Rock, Arkansas, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients must meet the ACR criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites.
Patients must complete the double-blind study.

Exclusion criteria

Patients who experienced a serious adverse event during the previous fibromyalgia study, which was determined to be related to the study medication.

Treatment and study plan

Pregabalin

Drug

Primary outcomes

To evaluate the safety of pregabalin in patients with fibromyalgia

Sponsors and collaborators

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Industry

Registry information

Official study title

A 12-Week, Open-Label, Safety Trial Of Pregabalin In Patients With Fibromyalgia

Important dates

Study start: 2006
Study completion: 2006
First posted: Jan 27, 2006
Registry last updated: Jan 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed